
GMDA Stock Forecast & Price Target
GMDA Analyst Ratings
Bulls say
Gamida Cell is a clinical-stage biopharmaceutical company with a promising immunotherapy pipeline utilizing NAM expansion technology, and boasts a strong financial position with $60.4 million cash on hand, only $81.4 million in convertible senior notes due at YE:24, and the potential for an additional $23.58 million from 17.467 million warrants with a $1.35 strike price. With a decreased projected market cap of $338 million and 151.5 million diluted YE:24E shares, the company's stock is currently valued at $2, indicating potential for growth in the future.
Bears say
Gamida Cell is facing several risks that contribute to the negative outlook, including potential underperformance of Omisirge sales, the possibility of GDA-201 failing in clinical trials, and the potential need for additional funding. Despite maintaining an Overweight rating, recent financials and updated metrics have led to a decreased price target of $2, reflecting a lower projected enterprise value of $437 million and anticipated dilution from ATM offerings. With slower than expected Omisirge launch and a lowered forecast of just $1.68 million in revenue for this year, Gamida Cell is exploring strategic funding options to fully support the launch. Additionally, while preliminary data for GDA-201 in Non-Hodgkin Lymphoma showed promise with a 40% ORR, full Phase I data is not expected until 1Q:24 and the company ended 3Q:23 with only $60.4 million in cash, enough to fund operations until 2Q:24.
This aggregate rating is based on analysts' research of Gamida Cell Ltd and is not a guaranteed prediction by Public.com or investment advice.
GMDA Analyst Forecast & Price Prediction
Start investing in GMDA
Order type
Buy in
Order amount
Est. shares
0 shares